Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls
Clin. transl. oncol. (Print)
; 14(1): 15-20, ene. 2012. tab, ilus
Artigo
em Inglês
| IBECS
| ID: ibc-126096
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
The serum cancer antigen 125 (CA-125) remains a reliable biomarker in the therapeutic management of epithelial ovarian cancer (EOC). Monitoring the efficacy of cytotoxic chemotherapy (CT) and the early detection of relapse during the follow up of patients in remission represent the two most common clinical situations where the CA-125 has been successfully applied. There are however other scenarios along the course of the disease where the CA-125 can potentially aid in the decision-making process. Preoperative levels of CA-125 can help in selecting a subset of patients where an optimal cytoreduction may not be easily achieved. Perioperative variations in the CA- 125 levels after primary surgery and, more importantly, the nadir value of the CA-125 after primary chemotherapy, are associated with patient outcome. This review focuses on the clinical relevance of dynamic changes in CA-125 levels during the primary treatment of EOC and its potential influence both in the patient management and in the design of clinical trials in the adjuvant setting (AU)
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Neoplasias Ovarianas
/
Neoplasias Epiteliais e Glandulares
/
Antígeno Ca-125
Tipo de estudo:
Estudo diagnóstico
/
Estudo prognóstico
/
Fatores de risco
/
Estudo de rastreamento
Limite:
Animais
/
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2012
Tipo de documento:
Artigo
Instituição/País de afiliação:
Hospital Universitario Madrid--Norte Sanchinarro/Spain
/
Hospital Universitario Vall d'Hebrón/Spain
/
University of Toronto/Canadá